Market Cap 183.17B
Revenue (ttm) 33.42B
Net Income (ttm) 4.09B
EPS (ttm) N/A
PE Ratio 15.79
Forward PE 16.23
Profit Margin 12.24%
Debt to Equity Ratio 5.67
Volume 2,897,700
Avg Vol 2,550,676
Day's Range N/A - N/A
Shares Out 538.48M
Stochastic %K 93%
Beta 0.45
Analysts Sell
Price Target $330.11

Company Profile

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of my...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 805 447 1000
Fax: 805 447 1010
Address:
One Amgen Center Drive, Thousand Oaks, United States
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 6 at 1:23 AM
Actionable Trade Alert for $AMGN: Market Context: $AMGN is currently trading at $340.16, positioned near its 60-day high of $346.38. The RSI at 53.93 indicates a neutral stance, suggesting potential for upward movement without being overbought. The moving averages (MA30 at 323.28 and MA50 at 310.82) show a bullish trend, with the current price above both, reinforcing a positive outlook. Directional Bias: Given the proximity to the 60D high and the bullish alignment of MAs, the bias is upward. The ATR of 7.14 indicates moderate volatility, allowing for a reasonable range for price movement. Trade Plan: - Suggested Entry: $340.50 - Stop Loss: $330.00 (risking $10.50) - Take Profit Targets: 1. $350.00 (3.50% gain) 2. $360.00 (5.80% gain) 3. $400.00 (17.6% gain) This plan offers a solid risk-reward ratio with a potential ROI exceeding 17% on the third target. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
ChoppaC
ChoppaC Dec. 5 at 5:00 PM
$AMGN run it back to 340’s
1 · Reply
profit_guru
profit_guru Dec. 5 at 4:18 PM
$AMGN - rotation back to health care into close from tech….solid pipeline, growth and dividend…near term 360…imo
0 · Reply
erpy
erpy Dec. 5 at 4:08 PM
$AMGN Way oversold rsi 11. Buying
1 · Reply
ChoppaC
ChoppaC Dec. 5 at 3:44 PM
$AMGN damn the one day I buy calls
0 · Reply
podfather
podfather Dec. 5 at 3:31 PM
$AMGN what's going on?
1 · Reply
albiegf13
albiegf13 Dec. 5 at 3:27 PM
0 · Reply
SparkyReturns
SparkyReturns Dec. 5 at 3:26 PM
$ICU Its unbelievable that the street hasn't picked up on this opportunity. * ICU * What other company has a market cap of only $12 Million but is launching a product with an annual market in the 10s of BILLIONS? [Read that again - 1000x] Patients' lives are saved and eliminates $100K/ year of dialysis dependency; Device has broad application for over a half dozen critical conditions (kidney, heart, ARDS, Sepsis, Covid, burns, etc); The device "sells itself" by saving hospitals $40K per average stay; Insurers will love it because their costs will go down; Government will love it to reduce number of Medicare patients on lifetime dialysis; FDA seems to be fast tracking all decisions, already gave grants; ZERO DEBT, and revenue ramping up. This may be the best time to get in for those looking for an investing idea. $TSLA $NVDA $JNJ $AMGN
2 · Reply
TrustButVerifi
TrustButVerifi Dec. 5 at 3:08 AM
$AMGN $LLY $VKTX that is not the reason! Total bullchet ! CNBC clowns need their heads out of their rectum. Bunch of fkn sheep! Just blow with the fkn wind! But above all BL needs to take some blame for this chit show ! He needs to get the fk on TV with Melissa and 3 stooges and explain the science!
2 · Reply
biolover
biolover Dec. 4 at 11:55 PM
$VKTX If all data and progress didn’t move SP and just this stupid FDA potential action did that to $VKTX 😂 , only shows u how deep MMs search biotechs and their assets. I am not convinced this is the reason. But u only need one large account to switch from $AMGN or $LLY to wreak havoc on shorts
1 · Reply
Latest News on AMGN
2 Dividend Stocks to Double Up On Right Now

Dec 1, 2025, 11:37 PM EST - 4 days ago

2 Dividend Stocks to Double Up On Right Now

KO


Dogs Of The Dow Continue Outperforming Broader Market

Nov 29, 2025, 1:45 AM EST - 7 days ago

Dogs Of The Dow Continue Outperforming Broader Market

DIA JNJ MAGS SPY


AMGEN TO PRESENT AT CITI'S 2025 GLOBAL HEALTHCARE CONFERENCE

Nov 24, 2025, 4:10 PM EST - 11 days ago

AMGEN TO PRESENT AT CITI'S 2025 GLOBAL HEALTHCARE CONFERENCE


Why Amgen Stock Edged Past the Market on Thursday

Nov 13, 2025, 5:36 PM EST - 22 days ago

Why Amgen Stock Edged Past the Market on Thursday


Trade Tracker: Bill Baruch buys more Amgen

Nov 13, 2025, 1:54 PM EST - 22 days ago

Trade Tracker: Bill Baruch buys more Amgen


Cramer's Stop Trading: Amgen

Nov 13, 2025, 10:30 AM EST - 22 days ago

Cramer's Stop Trading: Amgen


2 Supercharged Dividend Stocks to Buy Now

Nov 13, 2025, 10:07 AM EST - 22 days ago

2 Supercharged Dividend Stocks to Buy Now

GILD


Why Amgen Stock Was a Nearly 5% Winner Today

Nov 11, 2025, 5:31 PM EST - 24 days ago

Why Amgen Stock Was a Nearly 5% Winner Today


Three Healthcare Buys That Wall Street Loves

Nov 11, 2025, 10:50 AM EST - 24 days ago

Three Healthcare Buys That Wall Street Loves

ABBV LLY


Amgen CEO talks trial results of cardiac drug Repatha

Nov 10, 2025, 7:40 PM EST - 25 days ago

Amgen CEO talks trial results of cardiac drug Repatha


Amgen cholesterol drug cuts risk of first cardiac event by 25%

Nov 8, 2025, 10:11 AM EST - 27 days ago

Amgen cholesterol drug cuts risk of first cardiac event by 25%


Amgen: Buy This Cheap Biotech Leader

Nov 8, 2025, 12:11 AM EST - 4 weeks ago

Amgen: Buy This Cheap Biotech Leader


Stock Of The Day: Will Amgen Reverse Again?

Nov 6, 2025, 10:41 AM EST - 4 weeks ago

Stock Of The Day: Will Amgen Reverse Again?


Why Amgen Stock Was Crushing It on Wednesday

Nov 5, 2025, 2:26 PM EST - 4 weeks ago

Why Amgen Stock Was Crushing It on Wednesday


Amgen: Q3 Earnings Indicate Strong Emphasis On R&D

Nov 5, 2025, 12:40 PM EST - 4 weeks ago

Amgen: Q3 Earnings Indicate Strong Emphasis On R&D


Amgen Inc. (AMGN) Q3 2025 Earnings Call Transcript

Nov 4, 2025, 7:36 PM EST - 4 weeks ago

Amgen Inc. (AMGN) Q3 2025 Earnings Call Transcript


AMGEN REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS

Nov 4, 2025, 4:01 PM EST - 4 weeks ago

AMGEN REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS


AMGEN ANNOUNCES 2025 FOURTH QUARTER DIVIDEND

Oct 31, 2025, 4:01 PM EDT - 5 weeks ago

AMGEN ANNOUNCES 2025 FOURTH QUARTER DIVIDEND


AMGEN ANNOUNCES WEBCAST OF 2025 THIRD QUARTER FINANCIAL RESULTS

Oct 29, 2025, 4:01 PM EDT - 5 weeks ago

AMGEN ANNOUNCES WEBCAST OF 2025 THIRD QUARTER FINANCIAL RESULTS


1 Top Dividend Growth Stock to Buy Right Now

Oct 24, 2025, 10:00 AM EDT - 6 weeks ago

1 Top Dividend Growth Stock to Buy Right Now


4 Reasons to Buy Amgen Stock Right Now

Oct 4, 2025, 6:45 AM EDT - 2 months ago

4 Reasons to Buy Amgen Stock Right Now


Cramer's Stop Trading - Amgen

Oct 3, 2025, 10:22 AM EDT - 2 months ago

Cramer's Stop Trading - Amgen


Amgen Shares Cross Above 200 DMA

Oct 1, 2025, 11:35 AM EDT - 2 months ago

Amgen Shares Cross Above 200 DMA


PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 6 at 1:23 AM
Actionable Trade Alert for $AMGN: Market Context: $AMGN is currently trading at $340.16, positioned near its 60-day high of $346.38. The RSI at 53.93 indicates a neutral stance, suggesting potential for upward movement without being overbought. The moving averages (MA30 at 323.28 and MA50 at 310.82) show a bullish trend, with the current price above both, reinforcing a positive outlook. Directional Bias: Given the proximity to the 60D high and the bullish alignment of MAs, the bias is upward. The ATR of 7.14 indicates moderate volatility, allowing for a reasonable range for price movement. Trade Plan: - Suggested Entry: $340.50 - Stop Loss: $330.00 (risking $10.50) - Take Profit Targets: 1. $350.00 (3.50% gain) 2. $360.00 (5.80% gain) 3. $400.00 (17.6% gain) This plan offers a solid risk-reward ratio with a potential ROI exceeding 17% on the third target. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
ChoppaC
ChoppaC Dec. 5 at 5:00 PM
$AMGN run it back to 340’s
1 · Reply
profit_guru
profit_guru Dec. 5 at 4:18 PM
$AMGN - rotation back to health care into close from tech….solid pipeline, growth and dividend…near term 360…imo
0 · Reply
erpy
erpy Dec. 5 at 4:08 PM
$AMGN Way oversold rsi 11. Buying
1 · Reply
ChoppaC
ChoppaC Dec. 5 at 3:44 PM
$AMGN damn the one day I buy calls
0 · Reply
podfather
podfather Dec. 5 at 3:31 PM
$AMGN what's going on?
1 · Reply
albiegf13
albiegf13 Dec. 5 at 3:27 PM
0 · Reply
SparkyReturns
SparkyReturns Dec. 5 at 3:26 PM
$ICU Its unbelievable that the street hasn't picked up on this opportunity. * ICU * What other company has a market cap of only $12 Million but is launching a product with an annual market in the 10s of BILLIONS? [Read that again - 1000x] Patients' lives are saved and eliminates $100K/ year of dialysis dependency; Device has broad application for over a half dozen critical conditions (kidney, heart, ARDS, Sepsis, Covid, burns, etc); The device "sells itself" by saving hospitals $40K per average stay; Insurers will love it because their costs will go down; Government will love it to reduce number of Medicare patients on lifetime dialysis; FDA seems to be fast tracking all decisions, already gave grants; ZERO DEBT, and revenue ramping up. This may be the best time to get in for those looking for an investing idea. $TSLA $NVDA $JNJ $AMGN
2 · Reply
TrustButVerifi
TrustButVerifi Dec. 5 at 3:08 AM
$AMGN $LLY $VKTX that is not the reason! Total bullchet ! CNBC clowns need their heads out of their rectum. Bunch of fkn sheep! Just blow with the fkn wind! But above all BL needs to take some blame for this chit show ! He needs to get the fk on TV with Melissa and 3 stooges and explain the science!
2 · Reply
biolover
biolover Dec. 4 at 11:55 PM
$VKTX If all data and progress didn’t move SP and just this stupid FDA potential action did that to $VKTX 😂 , only shows u how deep MMs search biotechs and their assets. I am not convinced this is the reason. But u only need one large account to switch from $AMGN or $LLY to wreak havoc on shorts
1 · Reply
biolover
biolover Dec. 4 at 5:18 PM
$VKTX Could be rumor. Could be GPCR leak Could be an institution switching from $AMGN to $VKTX. Non sense gap in Obesity assets value between the two. Or between VKTX ( BIC ) and any other obesity pharma value.
0 · Reply
albiegf13
albiegf13 Dec. 4 at 4:31 PM
1 · Reply
QuietTrader
QuietTrader Dec. 4 at 2:38 PM
$CRSP There have been rumors swirling for the past few months. What I'm hearing is that there may be multiple parties involved, including the rumored $VRTX and $AMGN. I wouldn't be surprised if $LLY throws her hat in the mix, as Eli Lilly is aggressively expanding into gene‑editing and biotech via acquisitions and collaborations. In 2025 alone, Lilly bought a gene‑editing firm (showing its willingness to invest in this space). I only hope they don't rush into decisions, because this company has the ingredients to succeed and do very well for its investors on its own.
1 · Reply
NetworkNewsWire
NetworkNewsWire Dec. 4 at 2:18 PM
Breakthrough Therapies Advance as Rare Disease Burden Intensifies Across Aging Populations $SNGX $AMGN $FOLD $CTOR $TNXP https://ibn.fm/GbzxS
0 · Reply
Venge
Venge Dec. 4 at 2:20 AM
$AMGN A beauty
0 · Reply
howardlindzon
howardlindzon Dec. 4 at 1:03 AM
0 · Reply
howardlindzon
howardlindzon Dec. 4 at 1:02 AM
$AMGN all time highs ....
0 · Reply
biolover
biolover Dec. 3 at 11:04 PM
$AMGN $VKTX On the Evercore meeting today analyst U Raffatt pushed hard ok $AMGN managment to answer if further wt loss seen beyond 15% ( requirement to enter maintenance part ) and management got around that and emphasized several times that data are “ descriptive “ and further wt loss to be looked at in ongoing phase 3. Very interesting dialogue to listen to
0 · Reply
biolover
biolover Dec. 3 at 10:36 PM
$VKTX $AMGN announced delay of MariTide maintenance trial results from Q4 into 2026. Recall they are including only patients who achieved 15% weight loss on part one I find it hard to imagine they will get more weight loss after another 52 weeks. Q3 month dosing is likely toxic due to drug fluctuations as we saw that with Q2 month dosing in part one ( NEJM )
0 · Reply
crosshairtrader
crosshairtrader Dec. 3 at 9:10 PM
$AMGN Watching for a potential break. $XBI
0 · Reply
ProKnifeCatcher87
ProKnifeCatcher87 Dec. 3 at 8:50 PM
$AMGN 20% haircut
0 · Reply
RunnerSignals
RunnerSignals Dec. 3 at 8:33 PM
$AMGN $AZN $CRVO $NCLH $PHR more stock upgrades today highlight top picks https://stocksrunner.com/news/2025-12-03-stock-upgrades-today-highlight-top-picks
0 · Reply